Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, addresses the importance of patient assistance programs.
Transcript:
How important are patient assistance programs offered by reference drug makers to the patient experience with biologic drugs?
Patient assistance and patient support programs offered by drug makers are critical for patients.
These programs are often a combination of financial support for out-of-pocket or co-pay costs, as well as ongoing help from a trained medical professional such as a nurse, with many offering 24-hour access to a nurse hotline for when a question or concern may keep a patient awake at night or some reassurance is being sought. Of course, these are not intended to take the place of a patient’s own healthcare professional team, but having qualified, trained medical professionals available on-call is a feature that we encourage all patients to take advantage of and to participate in, where appropriate.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.